Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.39 |
| ▸ | PARP1 | P09874 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17028392 | 0.86 | NOTUM (0.41) | NOTUMHCRTR1HCRTR2KEAP1L3MBTL1 | |
| SCHEMBL302446 | 0.86 | HCRTR1 (0.46) | MAPK9MAPK10NOTUMHCRTR1HCRTR2 | |
| SCHEMBL17910085 | 0.84 | HCRTR1 (0.52) | MAPK9MAPK10NOTUMHCRTR1HCRTR2 | |
| SCHEMBL17910087 | 0.84 | HCRTR1 (0.43) | MAPK9MAPK10NOTUMHCRTR1HCRTR2 | |
| SCHEMBL19554755 | 0.81 | PARP1 (0.40) | MAPK9MAPK10NOTUMHCRTR1HCRTR2 | |
| SCHEMBL19554756 | 0.80 | PARP1 (0.39) | MAPK9MAPK10NOTUMHCRTR1HCRTR2 | |
| SCHEMBL6429867 | 0.80 | MAPK9 (0.41) | MAPK9MAPK10NOTUMHCRTR1HCRTR2 | |
| SCHEMBL6429861 | 0.80 | BCAT2 (0.51) | MAPK9MAPK10PARP1NPC1KEAP1 | |
| SCHEMBL2754382 | 0.78 | GRM5 (0.43) | MAPK9MAPK10HCRTR1HCRTR2PARP1 | |
| SCHEMBL2754380 | 0.77 | GRM5 (0.45) | MAPK9MAPK10PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4850824-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| EP-1725544-A1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2005090333-A1 | 3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| EP-1567507-A1 | 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-08-31 | — | — | EP | claimed |
| WO-2004050642-A1 | 1, 2, 3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | claimed |
| EP-3661510-A1 | METHODS OF TREATING BEHAVIOR ALTERATIONS | Oryzon Genomics, S.A. (ES) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019025588-A1 | METHODS OF TREATING BEHAVIOR ALTERATIONS | ORYZON GENOMICS, S.A. (ES) | 2019-02-07 | — | — | WO | disclosed |
| EP-2655357-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | Merck Serono S.A. (CH) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
| EP-1567507-A1 | 1,2,3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050642-A1 | 1, 2, 3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |